Restaurant and food CEOs have been in the spotlight amid the rise of appetite suppressing GLP-1 drugs — first made popular by the diabetes treatment Ozempic. However, the impact of these highly-coveted medications will ripple across a variety of sectors including the alcohol business, according to a recent report by…